Table of Contents
ISRN AIDS
Volume 2014, Article ID 674906, 6 pages
http://dx.doi.org/10.1155/2014/674906
Research Article

Emergence of Drug Resistance in Human Immunodeficiency Virus Type 1 Infected Patients from Pune, India, at the End of 12 Months of First Line Antiretroviral Therapy Initiation

1Department of Microbiology, Azeezia Institute of Medical Sciences & Research, Kollam, Kerala, India
2DDGMS (IT) Office of Directorate General of Medical Services (Army) Integrated HQ of MoDAG's Branch, L Block, New Delhi, India
3Department of Microbiology, Army Hospital (Research & Referral), Delhi, India
4National JALMA Institute of Leprosy and other Mycobacterial Diseases (Indian Council of Medical Research), Agra, India
5National AIDS Research Institute (Indian Council of Medical Research), Pune, India

Received 4 February 2014; Accepted 16 March 2014; Published 10 April 2014

Academic Editors: F. Krebs, C. Petrovas, J. Poudrier, F. Tuluc, and F. Vaida

Copyright © 2014 Rajesh T. Patil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National AIDS Control Organisation: Annual report 2009-10, Department of AIDS Control Ministry of Health & Family Welfare, Government of India, 2011, http://www.nacoonline.org/.
  2. M. R. Jordan, D. E. Bennett, S. Bertagnolio, C. F. Gilks, and D. Sutherland, “World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites,” Antiviral Therapy, vol. 13, supplement 2, pp. 15–23, 2008. View at Google Scholar · View at Scopus
  3. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents: May 2013, http://www.naco.gov.in/NACO/About_NACO/.
  4. “Department of Human Health Services (DHHS) guidelines,” Contentfiles/Adult and Adolescents Guidelines, http://www.aidsinfo.nih.gov/.
  5. J. M. Coffin, “HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy,” Science, vol. 267, no. 5197, pp. 483–489, 1995. View at Google Scholar · View at Scopus
  6. S. G. Deeks, J. N. Martin, E. Sinclair et al., “Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1,” Journal of Infectious Diseases, vol. 189, no. 2, pp. 312–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. Sabin, T. Hill, F. Lampe et al., “UK Collaborative HIV Cohort, (UK CHIC) study Group. Treament exhaustion of HAART among individuals infected with HIV in UK: multicentre cohort study,” BMJ, vol. 49, pp. 306–309, 2005. View at Google Scholar
  8. R. W. Shafer, M. A. Winters, S. Palmer, and T. C. Merigan, “Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients,” Annals of Internal Medicine, vol. 128, no. 11, pp. 906–911, 1998. View at Google Scholar · View at Scopus
  9. V. Miller and B. A. Larder, “Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure,” Antiviral Therapy, vol. 6, supplement 3, pp. 25–44, 2001. View at Google Scholar · View at Scopus
  10. N. Kumarasamy, V. Madhavan, K. K. Venkatesh et al., “High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings,” Clinical Infectious Diseases, vol. 49, no. 2, pp. 306–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. N. Chaturbhuj, N. K. Hingankar, P. Srikantiah et al., “Transmitted HIV drug resistance among HIV-infected Voluntary Counseling and Testing Centers (VCTC) clients in Mumbai, India,” AIDS Research and Human Retroviruses, vol. 26, no. 8, pp. 927–932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. R. Thorat, D. N. Chaturbhuj, N. K. Hingankar et al., “Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India,” AIDS Res Hum Retroviruses, vol. 27, no. 12, pp. 1291–1297, 2011. View at Publisher · View at Google Scholar
  13. L. Rajesh, R. Karunaianantham, P. R. Narayanan, and S. Swaminathan, “Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients,” AIDS Research and Human Retroviruses, vol. 25, no. 11, pp. 1179–1185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. K. Lee, T. L. Kieffer, R. F. Siliciano, and R. E. Nettles, “HIV-1 viral load blips are of limited clinical significance,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 5, pp. 803–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. N. K. Hingankar, S. R. Thorat, A. Deshpande et al., “Initial virologic response and HIV drug resistance among HIV-Infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India,” Clinical Infectious Diseases, vol. 54, supplement 4, pp. S348–S354, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Sen, S. P. Tripathy, A. A. Patil, V. M. Chimanpure, and R. S. Paranjape, “High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India,” AIDS Research and Human Retroviruses, vol. 23, no. 10, pp. 1303–1308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Gupta, D. G. Saple, G. Nadkarni et al., “One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India,” AIDS Research and Human Retroviruses, vol. 26, no. 1, pp. 25–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. W. Shafer and J. M. Schapiro, “HIV-1 drug resistance mutations: an updated framework for the second decade of HAART,” AIDS Reviews, vol. 10, no. 2, pp. 67–84, 2008. View at Google Scholar · View at Scopus
  19. A. Deshpande, A. C. Jeannot, M. H. Schrive, L. Wittkop, P. Pinson, and H. J. Fleury, “Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines,” AIDS Research and Human Retroviruses, vol. 26, no. 3, pp. 343–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Sen, S. P. Tripathy, V. M. Chimanpure, A. A. Patil, R. D. Bagul, and R. S. Paranjape, “Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India,” AIDS Research and Human Retroviruses, vol. 23, no. 4, pp. 489–497, 2007. View at Publisher · View at Google Scholar · View at Scopus